Name
Asper Biogene OÜ
Registry code
14265334
VAT number
EE101984009
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
24.05.2017 (7)
Financial year
01.01-31.12
Capital
2 500.00 €
Activity
72111 - Research and experimental development on biotechnology
825 111 €
14 628 €
2%
1 765 €
(estimate is approximate)
346 818 €
9
Submitted
No tax arrears
4%
3%
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| OÜ Asper Biolab 11538286 | 100% - 2 500.00 EUR | - | - | |
| Hardi Tamm 09.10.1974 (49) | - | Board member | Indirect ownership | |
| Andrei Sõritsa 25.11.1961 (62) | - | - | Indirect ownership | |
| Katrin Tamm 11.05.1974 (50) | - | - | Indirect ownership | |
| Villem Aruoja 13.05.1969 (55) | - | - | - | Founder |
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Celvia CC AS 11673707 | 15% - 3 962.46 EUR | - | - | Shareholder |
| 2019 02.07.2020 | 2020 25.06.2021 | 2021 30.06.2022 | 2022 26.06.2023 | 2023 27.06.2024 | |
|---|---|---|---|---|---|
| Total Revenue | 681 879 € | 786 521 € | 651 969 € | 782 438 € | 825 111 € |
| Net profit (loss) for the period | 14 050 € | 40 641 € | 35 465 € | 155 811 € | 14 628 € |
| Profit Margin | 2% | 5% | 5% | 20% | 2% |
| Current Assets | 154 865 € | 134 445 € | 118 675 € | 234 590 € | 196 090 € |
| Fixed Assets | 168 952 € | 218 662 € | 303 812 € | 360 098 € | 295 524 € |
| Total Assets | 323 817 € | 353 107 € | 422 487 € | 594 688 € | 491 614 € |
| Current Liabilities | 133 344 € | 169 198 € | 203 113 € | 241 220 € | 123 518 € |
| Non Current Liabilities | 90 200 € | 42 995 € | 42 995 € | 21 278 € | 21 278 € |
| Total Liabilities | 223 544 € | 212 193 € | 246 108 € | 262 498 € | 144 796 € |
| Share Capital | - | - | - | - | - |
| Equity | 100 273 € | 140 914 € | 176 379 € | 332 190 € | 346 818 € |
| Employees | 14 | 13 | 11 | 9 | 9 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q1 | 80 266.52 € | 26 582.69 € | 29 171.83 € | 13 |
| 2023 Q4 | 113 168.83 € | 38 350.04 € | 24 728.79 € | 11 |
| 2023 Q3 | 58 419.76 € | 29 034.39 € | 24 125.52 € | 11 |
| 2023 Q2 | 96 245.27 € | 37 958.18 € | 25 547.45 € | 11 |
| 2023 Q1 | 105 519.53 € | 49 656.96 € | 26 424.63 € | 12 |
| 2022 Q4 | 51 713.93 € | 26 754.51 € | 25 455.35 € | 12 |
| 2022 Q3 | 49 688.43 € | 26 414.68 € | 24 261.75 € | 13 |
| 2022 Q2 | 55 023.82 € | 38 984.41 € | 26 882.57 € | 13 |
| 2022 Q1 | 67 087.74 € | 35 712.93 € | 30 893.14 € | 14 |
| 2021 Q4 | 74 855.41 € | 34 535.05 € | 29 915.18 € | 15 |
| 2021 Q3 | 121 202.71 € | 37 133.5 € | 34 527.35 € | 15 |
| 2021 Q2 | 122 842.16 € | 28 551.33 € | 27 991.17 € | 16 |
| 2021 Q1 | 111 404.96 € | 37 299.33 € | 36 184 € | 16 |
| 2020 Q4 | 113 866.48 € | 39 504.18 € | 33 145.57 € | 17 |
| 2020 Q3 | 100 004.35 € | 23 731.15 € | 23 384.02 € | 17 |
| 2020 Q2 | 208 138.77 € | 44 106.57 € | 33 952.64 € | 18 |
| 2020 Q1 | 164 897.38 € | 40 584.47 € | 36 743.15 € | 18 |
